Policy & Regulation

Green Pharmaceuticals’ SnoreStop Nasal Spray, previously marketed as “NasoSpray,” still is available even though agency officials on multiple occasions for a month recommended a recall after an April inspection found “gross microbial contamination” in one lot.

Des recherches montrent que l’asthme et le diabète de type 2 (DT2) sont liés au-delà du hasard, partageant des facteurs inflammatoires et métaboliques. Cette association souligne l’importance d’une surveillance accrue et d’une prise en charge adaptée pour prévenir les complications chez les patients

Following Energy and Commerce Health Subcommittee hearing about FDA’s human food and tobacco programs on 10 September, gap between what the trade groups, committee leadership and the FDA each want more of doesn’t appear to be shrinking.

This is a short description. This is a short description. This is a short description.

At one year, TikTok Shop conjures the early days of Amazon, representing the ‘Wild West’ of beauty ecommerce, said co-founders of private label and contract manufacturing company KO-Pack at the IBA Cosmetics Convergence Fall 2024 Virtual Symposium, “The Promise and Pitfalls of TikTok Shop.”

Week after publishing safety alert about OPMS Black Liquid Kratom “linked to serious adverse health effects, including death,” FDA announced market research “to understand and characterize emergent risk/safety and perceived benefits reportedly linked to kratom and psychedelics.” But it withdrew the study 10 days later.

Semi-annual regulatory agenda of non-binding target dates also sets December goal for an NPRM to recognize N-acetyl-L-cysteine as a lawful dietary ingredient. Like IND exemptions rule, item on NAC included for first time in FDA’s list.

In this installment of HBW Insight’s “Inside Regulatory Affairs” series, we hear from Sharee Crumbey and Monica Sharda, regulatory affairs specialists at The Honest Company, about the mounting challenges and rewards of the job.

Dietary supplements containing unauthorized novel foods were reported to the European Commission by national regulators on around 40 occasions in the second quarter of 2024.

California Senate Appropriations Committee suspends consideration of bill for current session after it and Judiciary Committee voted to recommend passing the bill earlier in session. Legislative sessions continue in Massachusetts and New Jersey with bills for similar restrictions.

Germany's Alzchem failed to convince the UK's health claims committee that daily creatine supplementation can contribute to improved cognitive function. 

The FTC says its final rule banning fake consumer reviews and testimonials will help to restore its depleted toolbox for obtaining civil penalties. The agency maintains the final rule’s benefits will greatly outweigh costs for honest companies increasingly set back by bad actors in the space.

The 9 September meeting on Iterum Therapeutics' oral sulopenem product for uncomplicated urinary tract infections marks the first fully in-person advisory committee drug review since the COVID-19 pandemic hit in early 2020.

Supergut brand owner Uplifting Results Labs makes Gut Healthy GLP-1 Booster prebiotic fiber mix along with its snack bars and meal-replacement shakes available through GNC. IHerb launches supplements addressing side GLP-1 effects including nausea and pain, loss of muscle mass and changing blood sugar levels.

With monographs@FDA portal down, agency moves to NextGen and extends comment period through 27 September for first OTC monograph change it proposed using its overhauled program other than 32 monographs finalizations required in 2020 legislation authorizing overhaul.

OTC sales edged up at Italy's Recordati in the first half of 2024 as higher demand for GI products and supplements offset a weaker cold & flu season.

Avista VC acquires OTC CMO Trillium; FDA deputy commissioner Jones to open CRN conference; AG1 founder steps down, COO moves up to CEO; ChromaDex hires general counsel; Ajinomoto, Shiru partner to develop sweet proteins; and change at ingredient provider LBB helm.

As it has every year since FSMA was passed in 2011, FDA doesn’t plan to impose reinspection fees until it publishes guidance for small businesses to request reductions. FY2025 budget proposal includes plan “to re-structure the fee programs to make it more administratively feasible to operate.”

Consumer health, particularly food supplements that make unauthorized medical or health claims, has been a key area of focus for the UK Advertising Standards Authority's recently introduced Active Ad Monitoring system, which captures ads by relevant advertisers from a range of social media platforms, and applies machine learning algorithms to identify and flag likely non-compliant ads, which are then sent to experts to review and act on. This infographic highlights recent ASA rulings against ads for supplements claiming to treat anxiety and stress, menopause, autism/ADHD and weight loss, which were flagged by AI.

Unauthorized medical or health claims for dietary supplements are a key focus area for the UK advertising regulator's new AI-powered Active Ad monitoring system. HBW Insight speaks to the ASA’s head of data science, Adam Davison, in this exclusive interview to find out more about the organization's journey towards pre-emptive regulation.